Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment

By Adria Calatayud

Roche Holding said it received approval from the U.S. Food and Drug Administration for Vabysmo as treatment of macular edema following retinal vein occlusion, the drug's third indication.

The Swiss pharmaceutical giant said Friday that the approval was based on two late-stage studies that demonstrated early and sustained vision improvements.

Vabysmo is already approved for so-called "wet" age-related macular degeneration and diabetic macular edema, Roche said.

Write to Adria Calatayud at [e-mail]

(END) Dow Jones Newswires

10-27-23 0125ET